News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
550,909 Results
Type
Article (46556)
Company Profile (120)
Press Release (504222)
Multimedia
Podcasts (141)
Webinars (19)
Section
Business (145722)
Career Advice (2418)
Deals (28113)
Drug Delivery (141)
Drug Development (68500)
Employer Resources (158)
FDA (15964)
Job Trends (12065)
News (265499)
Policy (29900)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2313)
Academic (1)
Accelerated approval (34)
Adcomms (36)
Allergies (132)
Alliances (36151)
ALS (162)
Alzheimer's disease (1701)
Antibody-drug conjugate (ADC) (311)
Approvals (16107)
Artificial intelligence (485)
Autoimmune disease (152)
Automation (32)
Bankruptcy (312)
Best Places to Work (9198)
BIOSECURE Act (23)
Biosimilars (190)
Biotechnology (70)
Bladder cancer (157)
Brain cancer (54)
Breast cancer (583)
Cancer (4493)
Cardiovascular disease (408)
Career advice (2045)
Career pathing (38)
CAR-T (256)
CDC (59)
Celiac Disease (1)
Cell therapy (711)
Cervical cancer (35)
Clinical research (58769)
Collaboration (1458)
Company closure (4)
Compensation (1137)
Complete response letters (72)
COVID-19 (2719)
CRISPR (86)
C-suite (758)
Cystic fibrosis (141)
Data (5722)
Decentralized trials (2)
Denatured (32)
Depression (143)
Diabetes (476)
Diagnostics (5526)
Digital health (33)
Diversity (7)
Diversity, equity & inclusion (43)
Drug discovery (212)
Drug pricing (221)
Drug shortages (33)
Duchenne muscular dystrophy (233)
Earnings (62168)
Editorial (65)
Employer branding (20)
Employer resources (141)
Events (81775)
Executive appointments (881)
FDA (18998)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (20)
Funding (1255)
Gene editing (191)
Generative AI (42)
Gene therapy (596)
GLP-1 (1061)
Government (4188)
Grass and pollen (8)
Guidances (376)
Healthcare (14878)
HIV (56)
Huntington's disease (49)
IgA nephropathy (84)
Immunology and inflammation (283)
Immuno-oncology (55)
Indications (93)
Infectious disease (2972)
Inflammatory bowel disease (181)
Inflation Reduction Act (14)
Influenza (104)
Intellectual property (231)
Interviews (453)
IPO (14130)
IRA (57)
Job creations (3173)
Job search strategy (1671)
JPM (66)
Kidney cancer (16)
Labor market (81)
Layoffs (617)
Leadership (39)
Legal (7014)
Liver cancer (90)
Longevity (12)
Lung cancer (591)
Lymphoma (350)
Machine learning (40)
Management (52)
Manufacturing (722)
MASH (165)
Medical device (11567)
Medtech (11610)
Mergers & acquisitions (14967)
Metabolic disorders (1299)
Multiple sclerosis (140)
NASH (22)
Neurodegenerative disease (317)
Neuropsychiatric disorders (96)
Neuroscience (2885)
Neurotech (1)
NextGen: Class of 2026 (4997)
Non-profit (3189)
Now hiring (30)
Obesity (651)
Opinion (276)
Ovarian cancer (151)
Pain (188)
Pancreatic cancer (214)
Parkinson's disease (275)
Partnered (26)
Patents (469)
Patient recruitment (441)
Peanut (53)
People (44149)
Pharmaceutical (33)
Pharmacy benefit managers (32)
Phase 1 (17639)
Phase 2 (25434)
Phase 3 (20836)
Pipeline (4822)
Policy (332)
Postmarket research (2207)
Preclinical (7135)
Press Release (28)
Prostate cancer (237)
Psychedelics (54)
Radiopharmaceuticals (242)
Rare diseases (866)
Real estate (4301)
Recruiting (64)
Regulatory (23117)
Reports (40)
Research institute (2111)
Resumes & cover letters (403)
Rett syndrome (27)
RNA editing (16)
RSV (72)
Schizophrenia (151)
Series A (215)
Series B (171)
Service/supplier (8)
Sickle cell disease (95)
Special edition (25)
Spinal muscular atrophy (139)
Sponsored (46)
Startups (2787)
State (1)
Stomach cancer (20)
Supply chain (104)
Tariffs (101)
The Weekly (108)
Vaccines (1083)
Venture capital (94)
Weight loss (460)
Women's health (71)
Worklife (22)
Date
Last 7 days (542)
Last 30 days (1954)
Last 365 days (28056)
2026 (2642)
2025 (28398)
2024 (31403)
2023 (34987)
2022 (45063)
2021 (48501)
2020 (45515)
2019 (36209)
2018 (27398)
2017 (27804)
2016 (25805)
2015 (27975)
2014 (21775)
2013 (17793)
2012 (18963)
2011 (19382)
2010 (17512)
Location
Africa (686)
Alabama (66)
Alaska (6)
Arizona (227)
Arkansas (10)
Asia (32326)
Australia (5661)
California (10299)
Canada (2482)
China (903)
Colorado (402)
Connecticut (453)
Delaware (300)
Europe (78889)
Florida (1554)
Georgia (316)
Hawaii (4)
Idaho (39)
Illinois (732)
India (51)
Indiana (420)
Iowa (22)
Japan (395)
Kansas (104)
Kentucky (25)
Louisiana (19)
Maine (73)
Maryland (1278)
Massachusetts (7458)
Michigan (263)
Minnesota (549)
Mississippi (5)
Missouri (114)
Montana (12)
Nebraska (22)
Nevada (110)
New Hampshire (60)
New Jersey (2776)
New Mexico (15)
New York (2668)
North Carolina (1332)
North Dakota (7)
Northern California (5100)
Ohio (276)
Oklahoma (15)
Oregon (34)
Pennsylvania (1979)
Puerto Rico (16)
Rhode Island (32)
South America (1045)
South Carolina (63)
South Dakota (1)
Southern California (4003)
Tennessee (148)
Texas (1532)
United States (36030)
Utah (261)
Virginia (239)
Washington D.C. (73)
Washington State (825)
West Virginia (4)
Wisconsin (108)
Wyoming (1)
550,909 Results for "genmab a s".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Lymphoma
AbbVie, Genmab’s Bispecific Misses Key Overall Survival Endpoint in Phase III Lymphoma Study
Despite the late-stage miss, analysts maintained confidence in the Epkinly program, with Truist Securities saying the result “doesn’t waver our optimism” regarding the bispecific antibody’s ongoing frontline trial.
January 19, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Genmab Portfolio Prioritization Update
December 29, 2025
·
4 min read
Press Releases
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025
January 21, 2026
·
3 min read
Press Releases
Grant of Restricted Stock Units and Warrants to Employees in Genmab - January 29, 2026
January 30, 2026
·
4 min read
Press Releases
Genmab Portfolio Prioritization Update - December 29, 2025
December 29, 2025
·
4 min read
Press Releases
Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence
January 8, 2026
·
4 min read
Press Releases
Genmab to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 5, 2026
·
3 min read
Press Releases
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
November 20, 2025
·
3 min read
Antibody-drug conjugate (ADC)
Genmab Prunes Another ADC From $1.8B ProfoundBio Acquisition
Only one clinical-stage asset from the ProfoundBio acquisition remains in development: The antibody-drug conjugate Rina-S, in late-stage studies for ovarian and endometrial cancer.
November 18, 2025
·
2 min read
·
Tristan Manalac
Legal
AbbVie Lawsuit Alleges That Partner Genmab “Misappropriated” Trade Secrets
AbbVie claims that Genmab turned a blind eye to trade secret theft allegedly used to support the development of ProfoundBio’s investigational antibody-drug conjugates. Genmab acquired ProfoundBio in May 2024.
March 24, 2025
·
2 min read
·
Tristan Manalac
1 of 55,091
Next
